JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) (“Teva”) announced today that it successfully priced a debt offering by three of its special purpose finance subsidiaries, consisting of six tranches:
•$200,000,000 of three-month LIBOR + 0.80% floating rate senior notes maturing in May 2013 issued by Teva Pharmaceutical Finance IV, LLC (“Teva LLC”).
